CL2019003557A1 - Anticuerpos anti-trkb. - Google Patents

Anticuerpos anti-trkb.

Info

Publication number
CL2019003557A1
CL2019003557A1 CL2019003557A CL2019003557A CL2019003557A1 CL 2019003557 A1 CL2019003557 A1 CL 2019003557A1 CL 2019003557 A CL2019003557 A CL 2019003557A CL 2019003557 A CL2019003557 A CL 2019003557A CL 2019003557 A1 CL2019003557 A1 CL 2019003557A1
Authority
CL
Chile
Prior art keywords
trkb antibodies
trkb
antibodies
therapeutic
compositions
Prior art date
Application number
CL2019003557A
Other languages
English (en)
Inventor
Haiguang Xiao
Vladimir Voynov
Holger Rosenbrock
Remko Alexander Bakker
Rolf Herrmann
Sebastian Bandholtz
Peter Michael Benz
Michael Dziegelewski
Lore Florin
Cynthia Hess Kenny
Sarah Low
Sanjaya Singh
Heiko Friedrich Stahl
Sathyadevi Venkataramani
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2019003557A1 publication Critical patent/CL2019003557A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A ANTICUERPOS AGONISTAS ANTI-TRKB NOVEDOSOS Y MÉTODOS TERAPÉUTICOS Y DE DIAGNÓSTICO Y COMPOSICIONES PARA SU USO.
CL2019003557A 2017-06-09 2019-12-05 Anticuerpos anti-trkb. CL2019003557A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17175122 2017-06-09

Publications (1)

Publication Number Publication Date
CL2019003557A1 true CL2019003557A1 (es) 2020-05-04

Family

ID=59034551

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003557A CL2019003557A1 (es) 2017-06-09 2019-12-05 Anticuerpos anti-trkb.

Country Status (21)

Country Link
US (3) US10793634B2 (es)
EP (1) EP3635004A1 (es)
JP (2) JP7267208B2 (es)
KR (1) KR20200017421A (es)
CN (1) CN110719916A (es)
AR (1) AR112602A1 (es)
AU (1) AU2018279184A1 (es)
BR (1) BR112019023742A2 (es)
CA (1) CA3063965A1 (es)
CL (1) CL2019003557A1 (es)
CO (1) CO2019013718A2 (es)
EA (1) EA201992883A1 (es)
IL (1) IL271067B1 (es)
MA (1) MA49257A (es)
MX (1) MX2019014714A (es)
PE (1) PE20200173A1 (es)
PH (1) PH12019502694A1 (es)
SG (1) SG11201911814UA (es)
TW (2) TW202342100A (es)
UA (1) UA127967C2 (es)
WO (1) WO2018224630A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018277227A1 (en) * 2017-06-02 2019-10-31 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy
EP4232474A1 (en) * 2020-10-21 2023-08-30 Boehringer Ingelheim International GmbH Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7750122B2 (en) * 2005-06-06 2010-07-06 Wyeth Llc Anti-TrkB monoclonal antibodies and uses thereof
AU2007316418A1 (en) 2006-11-09 2008-05-15 Irm Llc Agonist TrkB antibodies and uses thereof
AU2007337809A1 (en) 2006-12-20 2008-07-03 Rinat Neuroscience Corporation TrkB agonists for treating autoimmune disorders
EP2205071B1 (en) * 2007-10-11 2015-07-22 Biogen MA Inc. Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma
EA201000603A1 (ru) * 2007-10-23 2010-12-30 Новартис Аг ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
WO2009092049A1 (en) 2008-01-17 2009-07-23 Irm Llc Improved anti-trkb antibodies
ES2435917T3 (es) 2008-02-04 2013-12-26 Lay Line Genomics S.P.A. Anticuerpos anti-Trk-A y derivados de los mismos
CA2732266A1 (en) 2008-07-28 2010-02-04 Emory University Treating various disorders using trkb agonists
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2011103667A1 (en) * 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
CN105566272A (zh) * 2010-06-09 2016-05-11 爱默蕾大学 TrkB激动剂及其用途
US9200080B2 (en) 2010-09-03 2015-12-01 Horacio Uri Saragovi Agonistic antibodies to TrkC receptors and uses thereof
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
EP3143043B1 (en) 2014-05-16 2022-12-14 Pfizer Inc. Bispecific antibodies with engineered ch1-cl interfaces
KR20180037994A (ko) 2015-07-28 2018-04-13 오토노미, 인코포레이티드 TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
US11078287B2 (en) 2015-11-17 2021-08-03 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
EP3717514A1 (en) 2017-11-30 2020-10-07 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use

Also Published As

Publication number Publication date
UA127967C2 (uk) 2024-02-28
EP3635004A1 (en) 2020-04-15
MA49257A (fr) 2020-04-15
US20240101689A1 (en) 2024-03-28
AU2018279184A1 (en) 2019-11-21
JP2023093621A (ja) 2023-07-04
TWI808086B (zh) 2023-07-11
PE20200173A1 (es) 2020-01-24
US10793634B2 (en) 2020-10-06
EA201992883A1 (ru) 2020-05-08
BR112019023742A2 (pt) 2020-06-09
AR112602A1 (es) 2019-11-20
CA3063965A1 (en) 2018-12-13
SG11201911814UA (en) 2020-01-30
IL271067B1 (en) 2024-02-01
JP7267208B2 (ja) 2023-05-01
CN110719916A (zh) 2020-01-21
JP2020522270A (ja) 2020-07-30
US11866501B2 (en) 2024-01-09
US20180355046A1 (en) 2018-12-13
CO2019013718A2 (es) 2020-01-17
TW201920271A (zh) 2019-06-01
PH12019502694A1 (en) 2020-07-13
KR20200017421A (ko) 2020-02-18
US20200399378A1 (en) 2020-12-24
TW202342100A (zh) 2023-11-01
WO2018224630A1 (en) 2018-12-13
IL271067A (en) 2020-01-30
MX2019014714A (es) 2020-02-07

Similar Documents

Publication Publication Date Title
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
DOP2018000175A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
BR112016025291A2 (pt) conjugados de anticorpo anti-ptk7-fármaco
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
BR112016014731A2 (pt) Anticorpos anti-baff
BR112016029860A2 (pt) conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
CL2019003557A1 (es) Anticuerpos anti-trkb.
BR112017002090A2 (pt) formulação de fator viii